Last reviewed · How we verify
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
Details
| Lead sponsor | Sumitomo Pharma America, Inc. |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 724 |
| Start date | 2014-06 |
| Completion | 2016-05 |
Conditions
- Adult Attention Deficit Hyperactivity Disorder
Interventions
- Dasotraline
Primary outcomes
- The incidence of AEs (or SAEs), and AEs (or SAEs) leading to discontinuation. — 12 months
Countries
United States